Cambrex, Dow partner to manufacture HPMCAS for drug solubility enhancement

Cambrex (NYSE: CBM) and The Dow Chemical Company (NYSE: DOW) have executed an agreement for Cambrex to contract manufacture Dow Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS) for Drug Solubility Enhancement.

This is the final step in building on the solubilization partnership that Dow and Bend Research announced in October 2012 and it will help Dow to commercially supply solubility enabling excipients. Construction has already begun on the new operational facility at Cambrex Karlskoga with commercial product availability set for year-end 2013. "Dow's polymer science and application expertise, coupled with Cambrex's capabilities positions Dow for rapid entry into the market. The AFFINISOL™ product platform has excellent manufacturing flexibility to match the diverse excipients needs of our customers' pipelines," said Bob Maughon , Senior R&D Director for Dow.

"We are enthusiastic about bringing the first solution of our AFFINISOL™ product range to the market," said Marc van Gerwen , Business Director for Dow. Van Gerwen added, "This agreement demonstrates our ability to promptly address with material science the pharmaceutical industry's most pressing need: advancing poorly soluble Active Pharmaceutical Ingredients to become therapeutically beneficial oral drug products."

"We are proud to be part of this collaboration with Dow," said Eric Neuffer , VP of Sales and Business Development for Cambrex. "This agreement between Dow and Cambrex further validates Cambrex's commitment to finding solutions that offer our clients quality products and services to meet a market need.  This has been a great partnership with both the Dow and Cambrex teams focused on achieving project goals and objectives in a timely manner."

SOURCE The Dow Chemical Company; Cambrex Corporation